Antigenics ROE 2025

Kaj počne Antigenics?

Antigenics Inc, now Agenus Inc, is a biotechnology company specializing in the research and development of innovative therapies for cancer and infectious diseases. The company is headquartered in Lexington, Massachusetts. The history of Antigenics begins in the late 1980s when the founder, Garo Armen, developed a method for identifying DNA sequences that encode specific proteins. The approach was based on the isolation of lentiviral vectors from human cells, which were then used to transfer the DNA sequences to other cells. This method allowed Antigenics to identify a variety of tumor-specific antigens (TSA) that could serve as potential targets for immunotherapies. In the 1990s, Antigenics focused on developing anti-tumor vaccines based on TSA. The first product was Oncophage, a vaccine made from individual TSA peptides isolated from the patient's tumor cells. Oncophage was tested in Phase II clinical trials in patients with various forms of cancer, including melanoma, renal cell carcinoma, and glioblastoma. Although the vaccine showed significant survival benefits in some studies, it was not approved in the United States. Today, Oncophage is used in Russia and India for the treatment of kidney cancer. In the late 2000s, Antigenics expanded its portfolio to include other immune-oncology approaches such as immune checkpoint protein CTLA-4 modulators, cytotoxic antibodies against cancer cells, and small molecules for immune activation. In 2014, the company was renamed Agenus Inc to reflect its expanded business model. Today, Agenus focuses on the development of immune combination therapies that combine various approaches to activate and modulate the immune system to achieve synergistic effects. The focus is on the use of immune checkpoint inhibitors that relieve T-cell inhibition, as well as the combination of vaccines and cytotoxic antibodies. Agenus' current products include immune checkpoint inhibitor CTLA-4 Ig, which is being tested in Phase III clinical trials for melanoma and lung cancer, and the QS-21 vaccine, which elicits a strong immune response and is used as an adjuvant for other vaccines for the treatment of infectious diseases. Agenus has various divisions, including a division for veterinary immunotherapies, which specializes in the development of vaccines and treatment methods for dogs and horses with cancer. Overall, Agenus has a rich history in the research and development of immunotherapies for the treatment of cancer and infectious diseases. Although the company has experienced setbacks in the past, it remains a key player in the field of immune-oncology and is expected to develop further groundbreaking therapies. Antigenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.